In addition to convenNonal MAM, a supplementary workflow was developed and implemented using an intact multi-attribute method (iMAM) which, using naNve or denaturing mass spectrometry analysis, allows the monitoring of most relevant CQAs at the intact level. Native intact protein analysis offers several advantages that include fast analysis Nmes and minimal sample preparaNon which results in reduced arNficially induced modificaNons and reduced variability . This workflow can be applicable both in the drug development and QC environment as a rapid screening method during downstream development or as an analytical tool for batch release testing, while offering unique and complementary information compared to standard MAM, especially on the protein assembly and degradation state . For this study a native size exclusion chromatography-mass spectrometry (SEC-MS) and native strong cation exchange chromatography-mass spectrometry (SCX-MS) iMAM workflow were assessed with the intention of evaluating their capabilities of monitoring CQAs and identifying whether the data obtained is comparable to results from the MAM workflow. For both the MAM and iMAM studies presented in this work, GLP-Fc fusion drug substance (DS) was used as the reference material and four commercial drug product (DP) batches were purchased for evaluation.